CVS to Return Over $37.7 Million

CVS has agreed to pay $37.76 million to settle allegations that it improperly dispensed and billed insulin pens to government healthcare programs over a ten‑year period.

According to the settlement:

• From 2010–2020, CVS pharmacies “dispensed more insulin pens than patients needed” and submitted reimbursement claims for premature or excessive refills.

  
  

• In many cases, pharmacies reported the maximum days‑of‑supply allowed, rather than the actual supply dispensed — masking over‑use and triggering ineligible reimbursement under federal and state programs.

  
  

• The settlement allocates approximately $24.45 million to the federal government, with the remainder distributed among several states.

  
  

This is not just a large dollar figure — it’s a clear enforcement signal.

Why This Matters to Compliance and Billing Teams

• Billing accuracy is non-negotiable: Insulin — especially packaged in pens or cartridges — presents unique challenges for pharmacies because of variable dosing, multi‑unit packaging, and PBM supply limits. As CVS acknowledged, those complexities “have long challenged pharmacies.”

  
  

• Refill policies and documentation must be robust: Misreporting days‑of‑supply or automating refills without validating patient need can lead to premature fills and false claims.

  
  

• Pharmacy operations oversight is essential: The government alleged that over‑dispensing was not isolated but systemic across many CVS stores — suggesting inadequate internal controls and compliance monitoring.

  
  

• Whistleblowers still matter: The case was triggered by whistleblower reports — reinforcing that internal reporting channels and legal protections remain critical for uncovering and correcting wrongdoing.

  
  

Key Takeaway for Health Systems, Pharmacies & Payers

Even well-known, large pharmacy chains are not immune from scrutiny — and a single long‑running compliance gap can lead to multi‑million‑dollar settlements. For compliance professionals, this case underscores the importance of:

• Rigorous medication dispensing controls

• Accurate days‑of‑supply and refill documentation

• Regular audits of pharmacy practices

• Effective whistleblower and oversight mechanisms

  
  

When pricing, packaging, and dosing intersect — as they often do with insulin pens — that’s where compliance risk can hide.